SCD and cancer: Further experiments showed that the combination of sorafenib and SCD1 inhibitors significantly elevated lipid peroxidation in cancer cells, the addition of ferrostatin-1 likewise reduced lipid peroxidation induced by the combination therapy (Fig. 3e and Supplementary Fig. 4i).